We are thrilled to welcome MedDRA Face-to-Face training from 08-09 June 2023.
MedDRA - the Medical Dictionary for Regulatory Activities - is a medical terminology used to classify adverse event information associated with the use of biopharmaceuticals and other medical products (e.g., medical devices and vaccines). Coding these data to a standard set of MedDRA terms allows health authorities and the biopharmaceutical industry to more readily exchange and analyse data related to the safe use of medical products. MedDRA is used to classify adverse event data from clinical trials; from spontaneous adverse event reports by health care professionals, patients and others; and from other sources of adverse event data.
MedDRA, developed by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), is continuously enhanced to meet the evolving needs of its users, who include regulators and industry worldwide. ICH has created a governance structure to nurture and protect the integrity of MedDRA. The ICH MedDRA Management Committee, appointed by the ICH Assembly, has overall responsibility for the direction of MedDRA, and oversees all the activities of the MedDRA Maintenance and Support Services Organisation.
Attendees of the face-to-face training sessions receive a certificate of course attendance. This certificate can be downloaded and printed from the MedDRA Self-Service Application.
To find out more about MedDRA Face-to-Face training 2023, click here.
Back to News
Latest Posts
-
FDA ImportShield Program Delivers Impressive Results in Stre...21 Jan 2026 -
FDA Takes Steps to Improve Gluten Ingredient Disclosure in F...21 Jan 2026
-
FDA Issues Guidance on Modernizing Statistical Methods for C...12 Jan 2026
-
FDA Increases Flexibility on Requirements for Cell and Gene...11 Jan 2026
-
FDA Finds Insufficient Data to Determine Safety of PFAS in C...29 Dec 2025